
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
Click the title above for a link to open the Pharmaceutical Executive September 2024 issue in an interactive PDF format.
about 2 years ago
A Care Sea Changeabout 2 years ago
Jan van de Winkel: Antibody Ascensionabout 2 years ago
Biotech Performance Pivot May Be in the Offingabout 2 years ago
Delivery and Disruption: Navigating a Changing Care Terrainabout 2 years ago
Outsourcing’s Evolution in the Pharma Industryabout 2 years ago
A Risk-Reward Reset: Getting Serious About Social Mediaabout 2 years ago
Copay Adjustment Chess Match: What Will Payers Do Next?about 2 years ago
Rx Power Struggle: How Pharma can Flip the PBM Script





